USE OF ERBB3 INHIBITORS IN THE TREATMENT OF TRIPLE NEGATIVE AND BASAL-LIKE BREAST CANCERS

摘要

Provided are methods of suppressing growth of triple negative breast tumors and basal-like breast tumors by contacting tumor cells with an ErbB3 inhibitor, e.g., an anti-ErbB3 antibody. Also provided are methods for treating triple negative breast cancer or basal-like breast cancer in a patient by administering to the patient an ErbB3 inhibitor, e.g., an anti-ErbB3 antibody. The treatment methods can further comprise selecting a patient having a triple negative breast cancer or basal-like breast cancer and then administering an ErbB3 inhibitor to the patient. The treatment methods also can further comprise administering at least one additional anti-cancer agent to the patient in combination with the ErbB3 inhibitor.

主权项

1. A method of treating triple negative breast cancer that expresses ErbB3, the method comprising administering, to a patient with a triple negative breast cancer tumor, an effective amount of an anti-ErbB3 antibody that immunospecifically binds to ErbB3 and:
i). inhibits EGF-like ligand-mediated phosphorylation of ErbB3, ii) decreases levels of ErbB3 on cell surfaces of cancer cells expressing ErbB3 by at least 10% relative to control, iii) stabilizes ErbB3 in a substantially inactive form, iv) reduces heregulin-induced formation of an ErbB2-ErbB3 protein complex in a cell which expresses ErbB2 and ErbB3, v) reduces heregulin-induced ErbB2 activation in a cell which expresses ErbB2 and ErbB3, vi) inhibits proliferation of cancer cells expressing ErbB3 by at least 10% relative to control, vii). inhibits VEGF secretion by cancer cells expressing ErbB3 by at least 10% relative to control, viii) inhibits migration of cancer cells expressing ErbB3 by at least 10% relative to control; ix) inhibits heregulin-, epiregulin-, epigen-, or biregulin-mediated signaling through ErbB; x) decreases the binding of one or more of heregulin, epiregulin, epigen or biregulin to ErbB3, relative to control by at least 10%; xi) substantially completely inhibits the binding of heregulin to ErbB3; or xii) inhibits phosphorylation of AKT.